Surface-active properties of vasoactive intestinal peptide

被引:15
作者
Önyüksel, H
Bodalia, B
Sethi, V
Dagar, S
Rubinstein, I [1 ]
机构
[1] Univ Illinois, Dept Pharmaceut, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Pharmacodynam, Chicago, IL 60612 USA
[3] Univ Illinois, Dept Bioengn, Chicago, IL 60612 USA
[4] Univ Illinois, Dept Med, Chicago, IL 60612 USA
[5] Chicago VA Healthcare Syst, W Side Div, Chicago, IL 60612 USA
关键词
surface tension; monolayer; critical micellar concentration; surfactant; phospholipids; neuropeptides; vasopressin;
D O I
10.1016/S0196-9781(00)00161-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of this study was to determine whether human vasoactive intestinal peptide (VIP) aggregates in aqueous solution and, if so, whether the peptide interacts with a biomimetic phospholipid monolayer and increases surface pressure. Using a custom-made Teflon trough containing HEPES buffer (pH 7.4) at room temperature and a surface tensiometer, we found that the critical micellar concentration (CMC) of VIP is 0.4 mu M. Surface pressure of a dipalmitoylphosphatidylcholine (DPPC) monolayer spread over the HEPES buffer declined significantly over 120 min because of phospholipid decomposition. However, injection of VIP at concentrations above CMC into the subphase of the monolayer elicited a significant concentration-dependent increase in surface pressure that persisted for 120 min (P < 0.05). Unlike VIP, injection of [(8)Arg]-vasopressin at an equimolar concentration only prevented the time-dependent decline in DPPC monolayer surface pressure. Taken together, these data indicate that human VIP aggregates in aqueous solution and expresses surface-active properties at physiological concentrations in vitro. We suggest that these attributes could have a role in modulating the bioactive effects of the peptide in vivo. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:419 / 423
页数:5
相关论文
共 50 条
  • [41] Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin
    Wilkins, BW
    Chung, LH
    Tublitz, NJ
    Wong, BJ
    Minson, CT
    JOURNAL OF APPLIED PHYSIOLOGY, 2004, 97 (04) : 1291 - 1298
  • [42] Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease
    Gonzalez-Rey, E
    Chorny, A
    Fernandez-Martin, A
    Varela, N
    Delgado, M
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (05) : 923 - 929
  • [43] CHARACTERIZATION OF VASOACTIVE-INTESTINAL-PEPTIDE RECEPTORS ON RAT ALVEOLAR MACROPHAGES
    SAKAKIBARA, H
    SHIMA, K
    SAID, SI
    AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 267 (03): : L256 - L262
  • [44] Expression of vasoactive intestinal peptide, substance P and bombesin-flanking peptide in nasal polyps
    Kuhn, AG
    Arnold, W
    ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 1996, 58 (04): : 229 - 232
  • [45] Vasoactive intestinal peptide and gastrin-releasing peptide play distinct roles in the suprachiasmatic nucleus
    Isobe, Y
    Nishino, H
    BRAIN RESEARCH BULLETIN, 1996, 40 (04) : 287 - 290
  • [46] Pinch-off in the presence of surface-active polymers
    Roche, M.
    Kellay, H.
    EPL, 2011, 95 (05)
  • [47] Abnormal Surface-Active Behavior of Perfluorooctanoates Induced by Salt
    Zhou Hongtao
    Gao Antao
    Xing Hang
    Gou Zhiming
    Xiao Jinxin
    ACTA CHIMICA SINICA, 2011, 69 (09) : 1035 - 1040
  • [48] Biological surface-active compounds from marine bacteria
    Nga Phuong Dang
    Landfald, Bjarne
    Willassen, Nils Peder
    ENVIRONMENTAL TECHNOLOGY, 2016, 37 (09) : 1151 - 1158
  • [49] Preparation and surface-active properties of telomer-type anionic surfactants from maleic anhydride
    Yoshimura, T
    Koide, Y
    Shosenji, H
    Esumi, K
    JOURNAL OF SURFACTANTS AND DETERGENTS, 2002, 5 (03) : 257 - 262
  • [50] CYSTIC-FIBROSIS, VASOACTIVE INTESTINAL POLYPEPTIDE, AND ACTIVE CUTANEOUS VASODILATION
    SAVAGE, MV
    BRENGELMANN, GL
    BUCHAN, AMJ
    FREUND, PR
    JOURNAL OF APPLIED PHYSIOLOGY, 1990, 69 (06) : 2149 - 2154